Source comparison
SS-31 Research: Clinical Trial vs Compounded Comparisons
Mechanism Cardiolipin binding + cristae stabilization Cardiolipin binding (if properly synthesized) Free radical scavenging only SS-31's structural mechanism is fundamentally different from scavenging. Antioxidants reduce ROS after formation, SS-31 prevents th
This comparison does not assign a generated winner or score.
- Mechanism
- Cardiolipin binding + cristae stabilization
- Cardiolipin binding (if properly synthesized)
- Free radical scavenging only
- SS-31's structural mechanism is fundamentally different from scavenging. Antioxidants reduce ROS after formation, SS-31 prevents the membrane disruption that drives ROS production
- Dosing Evidence
- Phase 2/3 trials at 1–4mg/day SC or 0.05–0.25mg/kg IV
- Extrapolated from published protocols
- Oral 100–400mg/day (CoQ10), varies widely
- Clinical trial dosing is calibrated to mitochondrial uptake kinetics. Compounded peptides must match these parameters to replicate outcomes
- Purity Verification
- FDA-compliant GMP manufacturing, batch testing
- Dependent on synthesis facility. HPLC verification required
- Supplement-grade standards (often <95% purity)
- Dimethyltyrosine synthesis is error-prone. Verify every batch or risk inactive product
- Half-Life
- 2–4 hours plasma, 24+ hours mitochondrial retention
- Identical if sequence is correct
- 6–8 hours (CoQ10), 24 hours (MitoQ)
- SS-31's mitochondrial persistence allows once-daily dosing despite short plasma half-life
- Clinical Outcome Data
- Published Phase 2 HFpEF, EMBRACE STEMI, Barth syndrome trials
- Case series and investigator-initiated studies
- Observational and small RCTs
- Only SS-31 has randomized controlled data in acute mitochondrial injury settings
- Cost Accessibility
- $3,000–$8,000/month (estimated commercial pricing)
- $200–$800/month depending on source
- $20–$100/month (CoQ10)
- Price reflects synthesis complexity and patent protection. Compounded access requires 503B pharmacy sourcing